By Nigel Somerville, the Deputy Sheriff of AIM | Sunday 20 September 2015
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
AIM-listed biotech play Scancell (SCLP) released its results to April 2015 on Friday morning, along with some further tit-bits from its ongoing Phase I/II clinical trial testing its lead SCIB-1 treatment for melanoma. Since my original write-up on this company (HERE) there have been a few refinements, but the investment proposition is essentially the same as ever: if the product gets through the regulatory drug trial process unscathed then Scancell should be worth a healthy multiple of its current market capitalisation.
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen